Biocryst Pharmaceuticals (BCRX) Gross Margin (2010 - 2026)

Biocryst Pharmaceuticals has reported Gross Margin for 16 years, with the latest figure at 96.56% in Q1 2026.

• For the quarter ending Q1 2026, Gross Margin fell 30.0% year-over-year to 96.56%; the trailing twelve-month figure through Mar 2026 stood at 95.86% (down 105.0% YoY), and the FY2025 full-year result was 97.82%, up 54.0% from the prior year.
• Gross Margin for Q1 2026 stood at 96.56%, up from 1244.92% in the prior quarter.
• The five-year high for Gross Margin was 99.62% in Q2 2022, with the low at 1244.92% in Q4 2025.
• Historically, Gross Margin has averaged 18.9% across 5 years, with a median of 98.33% in 2023.
• Annual changes were most pronounced in 2022 — Gross Margin jumped 3060 bps — and 2025, when it slumped 134028 bps.
• Biocryst Pharmaceuticals' Gross Margin stood at 97.0% in 2022, then climbed by 1 bps to 98.33% in 2023, then retreated by 3 bps to 95.37% in 2024, then slumped by 1405 bps to 1244.92% in 2025, then surged by 108 bps to 96.56% in 2026.
• The last three Gross Margin figures came in at 96.56% (Q1 2026), 1244.92% (Q4 2025), and 98.63% (Q3 2025), per Business Quant data.